UK News Novavax jab ‘desirable’ for future booster campaign
Vaccine Taskforce boss Bingham 'to be made a dame' for jab success
Venture capitalist Ms Bingham will be rewarded for her efforts during the Covid-19 pandemic, in the Queen's upcoming Birthday Honours list, according to the Sunday Telegraph. In her unpaid role as chair of the UK's Vaccine Taskforce she led procurement of vaccines and helped secure more than 350 million doses of seven different vaccines, including 40 million doses of the Pfizer/BioNTech vaccine, and 100 million doses of the jab developed by Oxford and AstraZeneca. Her ability to lead the UK's efforts to find a coronavirus jab was initially repeatedly questioned because she had no experience of buying vaccines.
The Novavax vaccine could be “desirable” for future booster campaigns, experts have said.
New clinical trial results showed the jab was 100% effective against preventing moderate or severe disease.
Britain has ordered 60 million doses of the vaccine.
NEW DATA RELEASE: NovavaxVaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Vaccine rollout reaches ‘home straight’ six months on from first jab
The Health Secretary has said it is still too early to say whether remaining restrictions will be lifted on June 21. © Jacob King The Covid-19 vaccine is being rolled out to the over-25s in England from Tuesday (Jacob King/PA) Health Secretary Matt Hancock announced that those aged 25 to 29 in England – around three million people – will be invited to book their jabs from Tuesday as the NHS hailed reaching the “home straight” of the biggest vaccination programme in its history.
— Novavax (@Novavax)
The firm said that it will be filing for regulatory approval by medicines regulators in the third quarter of the year.
It started a rolling review process with the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), in January.
It comes as the firm produced positive results from its clinical trial in the US and Mexico.
Almost 30,000 were enrolled in the Prevent-19 trial, which concluded that the vaccine is 90.4% effective overall and 100% effective against preventing moderate or severe disease.
Officials said that the findings also “reaffirm the ability of the vaccine to prevent Covid-19 amid ongoing genetic evolution of the virus” amid growing concern about new variants.
'Unlimited guests allowed at weddings' even if Freedom Day delayed
Plans are being drawn up to relax certain curbs from later this month, regardless of the decision ministers will make on a complete unlocking of restrictions. This includes lifting the current 30-person limit on weddings and receptions, and allowing far greater crowds to attend ceremonies, bringing it in line with the Government's policy on funerals.Bar mitzvahs and christenings are also set to be boosted under the proposals, and while socially distanced tables would not be required, guests may be urged to be 'cautious' about contact with other households, according to the Times.
The vaccine was also reported to be “well tolerated” with some participants reporting injection site pain and tenderness, and fatigue, headache and muscle pain.
The two-dose vaccine works in a different way to the jabs currently being used in the UK. It combines an engineered protein from the virus that causes Covid-19 with a plant-based ingredient to help generate an immune response.
Today, Novavax is excited to announce results of our PREVENT-19 Phase 3in the US & Mexico, evaulating the safety and efficacy of NVX-CoV2373, our investigational candidate. Thread:
— Novavax (@Novavax)
Dr Gregory Glenn, president of research and development at Novavax, told a briefing for journalists that the company was having “very active, constructive” discussions with the MHRA.
Gallery: The biggest medical advances of the 2010s (Espresso)
Corona vaccine from NovaVax is 93 percent against variants Effective
According to study, The Corona vaccine of the US Biotech Company Novavax has proven to be effective in COVID-19 in the final phase 3 study. This communicated the company from Maryland on Monday. Previously, smaller test series in the United Kingdom and South Africa had confirmed the high effectiveness of the two-phase vaccine. The data of the large study will now allow Novavax to submit the vaccine to the US pharmaceutical authority FDA.
On the mix and match studies in the UK – which are testing out a combination of different vaccines – he said: “They are looking at the safety and immunogenicity and I think (the researchers) are going to submit a letter to The Lancet on the safety so look for that this week.
“Overall our safety profile is very desirable for boosting.”
He added: “We’re aware of this timing need for boosting in the UK and we certainly have that in our sights and if at all possible that we can be involved in that we would like to be.
“What I can say as a vaccinologist and immunologist is that we are going to see immunity wane and you’re going to need a boost. I think the UK is rightly, from a public health standpoint, presuming that you’re going to need to boost people.
“Our vaccine is a recombinant vaccine, those are licenced, there is a tonne of experience with that from a safety standpoint as a platform.
“As people go out and start to contemplate the next step a lot of them will pay attention to the safety profile and I think our vaccine gives them a desirable option.”
He added that clinical trials had provided “incredible confirmation” that the vaccine was working well.
Thirty million second Covid-19 vaccine doses as NHS pledges to ‘finish the job’
Health officials have said that 57.3% of UK adults have had two jabs.The Department of Health and Social Care said that 57.3% of UK adults (30,204,738 million people) had had their second dose while almost four in five (79.4%) had received one dose.
“I think that’s going to be important information for those conducting boosting campaigns as well as for people who are selecting what they want to have done with their arm,” he said.
Asked about new variants, he added: “We’re trying to be ready – our technology allows us to make different vaccines.
“I do think this is encouraging, it looks like high-quality antibodies cover a lot of variation.”
Paul Heath, professor of paediatric infectious diseases and director of the Vaccine Institute at St George’s, University of London and St George’s Hospital, London, and chief investigator of the Novavax UK trial, said: “These preliminary results from the large US/Mexico Prevent-19 trial confirm the high efficacy and safety of the Novavax Covid-19 vaccine shown earlier in the year in the UK Novavax Vaccine Trial (an overall efficacy of 89%).
“The results are very reassuring and importantly show that this vaccine appears to be safe and effective in populations from a range of communities and demographic groups, and those with a range of underlying comorbidities, now (across both trials) with a total number of participants of more than 45,000.
“Both the UK and US/Mexico trials used the same case definitions, and these consistent results therefore provide much confidence in the use of this vaccine for the global population.
“We now await the peer-reviewed publication. We also look forward to the results of the trial’s adolescent arm – 12 to 17 years of age – which recently completed enrolment.”
Two sites have been enlisted to the production process in the UK for part of the manufacturing process for the jab – FUJIFILM Diosynth Biotechnologies’s facilities in Billingham, Stockton-on-Tees and the GSK site at Barnard Castle.
A MILLION Covid vaccines were booked over weekend in 'summer sprint' .
Officials are in a race to vaccinate younger adults in a bid to halt the spread of the Indian variant and thousands queued in the rain for jabs at Tottenham Hotspur's stadium in north London yesterday.Thousands queued in the rain for jabs at Tottenham Hotspur's stadium in north London yesterday after the football club turned into a walk-in vaccine clinic for the day. Most of those getting vaccinated were in their late teens or 20s.